ArticleMolecular diversity2026
Pan-cancer multi-omics characterization of CDK12 and virtual screening of Vietnamese natural products for novel inhibitors.
Article in Molecular diversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cyclin-dependent kinase 12 (CDK12), a key regulator of cell-cycle-linked transcriptional programs, has gained increasing attention as a driver of tumorigenesis and a promising therapeutic vulnerability across diverse malignancies. In this study, we combined pan-cancer multi-omics profiling with a computational screen of a Vietnamese medicinal herbs compound library to identify candidate inhibitors targeting both wild-type CDK12 and its drug-resistant C1039F variant. Transcriptomic and proteomic analyses of TCGA and GTEx datasets revealed significant CDK12 overexpression in 14 tumor types compared with matched normal tissues. Overall survival comparisons further indicated that elevated CDK12 expression predicts markedly poorer outcomes in different renal cancer types and glioma, whereas genomic profiling identified ovarian cancer as the malignancy with the highest frequency of CDK12 alterations. Immune deconvolution analyses showed strong associations between CDK12 expression and infiltration by endothelial cells and natural killer T cells, suggesting a link between CDK12 dysregulation and tumor immune evasion. Complementing the multi-omics investigation, molecular docking, molecular dynamics simulations, and MM/PBSA free-energy calculations were conducted to evaluate the binding profiles of natural compounds derived from Vietnamese medicinal plants against both CDK12 variants. Several phytochemicals including 2,3-Diepicastasterone from Phaseolus vulgaris (- 131.038 ± 23.572 kcal/mol), as well as compounds from Eurycoma longifolia and Oryza sativa-exhibited highly favorable binding affinities and stable interaction dynamics, highlighting them as promising scaffolds for CDK12 inhibitor development. Collectively, our findings establish CDK12 as a robust biomarker for cancer diagnosis, prognosis, and immune modulation, while highlighting natural-product-based scaffolds as promising leads for next-generation CDK12 inhibitors targeting both wild-type and resistant variants, potentially synergizing with emerging immuno-oncology strategies.
Indexed as
Identifiers
41706297What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.